# US 2015/0105428 A1 · Compositions and methods for modulating circadian synchronization

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105428 A1
- Document ID: US20150105428A1
- Status: Published application
- Kind: A1
- Application number: 14/573,638
- Filed: 2014-12-17
- Published: 2015-04-16
- Earliest claimed: 2011-03-10
- Assignees: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.
- Applicants: Max-Planck-Gesellschaft-zur-Förderung der Wissenschaften e.V.
- Inventors: Gregor Eichele; Henrik Oster; Silke Kiessling
- Web page: https://patentgrep.com/patent/US20150105428A1

## CPC

- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a modulator of glucocorticoid biosynthesis, degradation and/or receptor activation for use in preventing or treating symptoms and/or diseases associated with jet lag. The compositions of the invention may be used as a lead compound for developing a drug for preventing or treating symptoms and/or diseases associated with jet lag. The invention relates to the discovery that administration of the modulator(s) to a subject results in a directional change of the time point of maximum amounts of glucocorticoids in the subject as compared to the time point of maximum amounts of glucocorticoids in a subject not treated with the modulator(s).

## Claims

### Claim 1

A method of preventing or treating symptoms and/or diseases associated with jet lag comprising administering to a subject in need thereof a pharmaceutically effective amount of a modulator of glucocorticoid biosynthesis, wherein the modulator inhibits the conversion of 11-deoxycortisol to cortisol.

### Claim 2 (depends on 1)

The method of claim 1 wherein the modulator is a modulator of Cyp11b1 and/or Cyp11b2.

### Claim 3 (depends on 1)

The method of claim 1 wherein the symptoms and/or diseases associated with jet lag are selected from the group consisting of sleep disruption, impaired cognitive skills, loss of appetite, depression, reduced psychomotor coordination, gastrointestinal disturbances, decreased alertness, malignant cell growth, temporal lobe atrophy and cardiomyopathies.

### Claim 4 (depends on 3)

The method of claim 3, wherein the amplitude of maximum glucocorticoid amounts is not significantly altered.

### Claim 5 (depends on 3)

The method of claim 3, wherein the time point of maximum amounts of glucocorticoids in a subject treated with said modulator is earlier than the time point of maximum amounts of glucocorticoids from a subject not treated with the modulator and wherein this earlier time point results from the administration of the modulator in the first half of the rest phase of the subject to be treated.

### Claim 6 (depends on 3)

The method of claim 3, wherein the time point of maximum amounts of glucocorticoids in a subject treated with the modulator is later than the time point of maximum amounts of glucocorticoids from a subject not treated with the modulator and wherein this later time point results from the administration of the modulator in the first half of the active phase of the subject to be treated.

### Claim 7 (depends on 1)

The method of claim 1 wherein the modulator is administered at least one time prior to and/or at the time of initiating activities that cause jet-lag.

### Claim 8 (depends on 7)

The method of claim 7 wherein the modulator is administered once a day.

### Claim 9 (depends on 1)

The method of claim 1 wherein the modulator is a small organic molecule.

### Claim 10 (depends on 9)

The method of claim 9 wherein the modulator is selected from FAD286, aryl methyl sulfones, metyrapone, etomidate, or FAD.
